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ABSTRACT
Purpose: The lack of biomarkers that can distinguish aggressive from indolent 
prostate cancer has caused substantial overtreatment of clinically insignificant 
disease. Here, by genome-wide DNA methylome profiling, we sought to identify new 
biomarkers to improve the accuracy of prostate cancer diagnosis and prognosis.
Experimental design: Eight novel candidate markers, COL4A6, CYBA, TCAF1 
(FAM115A), HLF, LINC01341 (LOC149134), LRRC4, PROM1, and RHCG, were selected 
from Illumina Infinium HumanMethylation450 BeadChip analysis of 21 tumor (T) 
and 21 non-malignant (NM) prostate specimens. Diagnostic potential was further 
investigated by methylation-specific qPCR analysis of 80 NM vs. 228 T tissue samples. 
Prognostic potential was assessed by Kaplan-Meier, uni- and multivariate Cox 
regression analysis in 203 Danish radical prostatectomy (RP) patients (cohort 1), 
and validated in an independent cohort of 286 RP patients from Switzerland and the 
U.S. (cohort 2).
Results: Hypermethylation of the 8 candidates was highly cancer-specific (area 
under the curves: 0.79-1.00). Furthermore, high methylation of the 2-gene panel 
RHCG-TCAF1 was predictive of biochemical recurrence (BCR) in cohort 1, independent 
of the established clinicopathological parameters Gleason score, pathological tumor 
stage, and pre-operative PSA (HR (95% confidence interval (CI)): 2.09 (1.26 - 3.46); 
P = 0.004), and this was successfully validated in cohort 2 (HR (95% CI): 1.81 (1.05 
- 3.12); P = 0.032).
Conclusion: Methylation of the RHCG-TCAF1 panel adds significant independent 
prognostic value to established prognostic parameters for prostate cancer and thus 
may help to guide treatment decisions in the future. Further investigation in large 
independent cohorts is necessary before translation into clinical utility.
INTRODUCTION
Prostate cancer is the most commonly diagnosed 
non-cutaneous malignancy in men in the Western world 
[1]. The diagnosis is based on elevated serum PSA 
(prostate-specific antigen), suspicious digital rectal 
examination and histopathologic evaluation of the sampled 
biopsies. Unfortunately, the currently available routine 
prognostic tools (mainly Gleason score (GS), serum 
PSA, and tumor stage) are unable to clearly distinguish 
aggressive from indolent disease at the time of diagnosis. 
Moreover, the lack of biomarkers for aggressive disease, 
Oncotarget2www.impactjournals.com/oncotarget
combined with opportunistic PSA screening, has led to 
large scale overdiagnosis and overtreatment of clinically 
insignificant prostate cancers, thus new biomarkers are 
urgently needed.
Methylation of CpG dinucleotides in promoter 
regions is an essential mechanism of long-term 
gene silencing. In human malignancies, aberrant 
hypermethylation of promoter-associated CpG islands 
(CGIs) is a well-established mechanism for tumor 
suppressor gene (TSG) silencing [2]. While recurrent 
somatic mutations are rare in prostate cancer, aberrant 
promoter hypermethylation occurs early and more 
consistently in tumor development and progression, 
and thus constitutes a promising source for discovery of 
novel biomarkers. Indeed, DNA methylation alterations 
have shown significant potential as diagnostic as well as 
prognostic biomarkers for prostate cancer [3].
Here, we performed genome-wide DNA methylation 
profiling of 21 tumor (T) and 21 non-malignant (NM) 
prostate tissue specimens using the Illumina Infinium 
HumanMethylation450 BeadChip (450K array), and 
selected 8 novel methylation marker candidates associated 
to the promoter regions of 8 genes for further investigation: 
COL4A6 (collagen, type IV, alpha 6), CYBA (cytochrome 
b-245, alpha polypeptide), TCAF1 (TRPM8 channel-
associated factor 1 (previously FAM115A)), HLF (hepatic 
leukemia factor), LINC01341 (long intergenic non-protein 
coding RNA 1341 (previously LOC149134)), LRRC4 
(leucine rich repeat containing 4), PROM1 (prominin 1), 
and RHCG (Rh family, C glycoprotein). Hypermethylation 
of all candidates was highly cancer-specific in surgical 
specimens as well as in diagnostic needle biopsy samples 
(DNBs, area under the curves (AUCs): 0.79-1.00). Finally, 
a 2-gene panel comprising RHCG and TCAF1 methylation 
was developed in the training cohort (203 Danish 
prostate cancer patients) and successfully validated in the 
validation cohort (286 Swiss/American prostate cancer 
patients) where it added significant independent prognostic 
value to routine clinicopathological parameters. This is the 
first study to show a prognostic biomarker potential for 
RHCG and TCAF1 methylation in prostate cancer.
RESULTS
Identification and validation of candidate 
methylation markers
To identify novel candidate markers for prostate 
cancer, global DNA methylation analysis was performed 
in 21 T, 12 adjacent normal (AN), and 9 true normal 
(N) prostate tissue samples (Table S1), in addition to 
3 malignant (PC3, LNCaP, 22rv1) and 2 NM (PrEC, 
BPH1) prostate cell lines using the Illumina 450K array. 
By multi-dimensional scaling analysis, tumor samples 
showed highly distinct and heterogenous methylation 
patterns compared to AN and N samples, which clustered 
tightly together (Figure 1A). No significant differential 
methylation was observed between AN and N samples 
Figure 1: Differential methylation (T vs. NM) according to Illumina 450K array. A. Multi-dimensional scaling plot of samples 
included in 450K analysis, based on the 10,000 most variable CpG sites across all samples. T samples (N = 21): Triangles; AN samples 
(N = 12): Circles; N samples (N = 9): Crosses. B.-E. Distribution of differential methylation (T vs. NM) according to the 450K array. 
Differentially methylated CpG sites (DMCs) were defined as CpG sites with Δβ ≥ │0.2│ and adj. P < 0.05. B. Differential methylation 
across all probes. C. Distribution of DMCs. D. Distribution of hypermethylated DMCs. E. Distribution of hypomethylated DMCs. 
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(LIMMA differential methylation analysis [4], data not 
shown), which were thus pooled into one NM sample 
group. By comparing methylation in T vs. NM samples, 
we identified 37,763 differentially methylated CpG sites 
(DMCs: mean Δβ ≥ │0.2│, adj. P < 0.05), the majority 
of which were hypermethylated (N = 29,748, Figure 1B) 
and CGI-associated (Figure 1C, 1D). Conversely, most of 
the 8,015 DMCs displaying significant hypomethylation 
in tumors were located outside CGIs (Figure 1E). 
Thus, we observed cancer-specific hypermethylation 
of CGIs, whereas CpG sites outside CGIs were largely 
hypomethylated, consistent with previous reports of 
methylation patterns in cancer, including prostate cancer 
[2]. 
To identify candidate biomarkers exhibiting highly 
cancer-specific differential methylation, we applied a strict 
threshold (mean Δβ ≥ │0.55│), generating a shortlist 
of the most differentially methylated CpGs (N = 324). 
Next, filtering for gene association (according to Illumina 
annotations) generated a final list of 259 top candidate 
DMCs (adj. P < 0.05, mean Δβ > │0.55│), associated 
to 163 genes (Figure 2A, Table S2). In addition to many 
novel candidates, this list contained several genes known 
to be frequently hypermethylated in prostate cancer 
(e.g. GSTP1, RARB [5]), supporting the validity of our 
results. From this list, 8 novel top candidate genes were 
selected based on their display of highly cancer-specific 
hypermethylation over multiple adjacent promoter-
associated DMCs: COL4A6, CYBA, HLF, LINC0134 
(LOC149234), LRRC4, PROM1, RHCG, and TCAF1 
(FAM115A) (Figure 2B, S1 and S2, Table S3). None of 
these candidates have been previously investigated as 
potential prostate cancer methylation markers. 
For technical validation of the 450K array data, 
methylation levels of the 8 candidates were investigated 
by bisulfite sequencing (BS) in the 5 prostate cell lines. 
BS showed low methylation levels in NM cell lines 
(PrEC, BPH1) and high levels in malignant cell lines 
(PC3, LNCaP, 22rv1) for all 8 candidates, and fully 
corroborated the 450K results for these cell lines (Figure 
S3). Notably, by both 450K and BS analysis, we observed 
the same methylation patterns for NM vs. malignant 
Figure 2: Selection of biomarker candidates. A: Candidate selection process. Of the 324 top candidate significant DMCs, 259 were 
associated to a total of 163 different genes. Eight genes were selected for further validation. B: Mean methylation of representative DMCs 
for each selected candidate in T and NM samples according to the discovery 450K dataset (T, N=21; NM, N=21). C: Mean methylation 
of the same DMCs as in (B) for each candidate in T and NM samples according to the TCGA 450K dataset for prostate cancer (T, N=297; 
NM, N=34).” . 
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cell lines, as was observed for NM vs. malignant tissue 
specimens in the 450K analysis. Moreover, we performed 
in-silico validation using 450K data from The Cancer 
Genome Atlas (TCGA) [6, 7] for 297 T and 34 AN 
prostate specimens, which independently confirmed 
prostate cancer-specific hypermethylation of all 8 genes 
(Figure 2C, Table S3). Finally, in order to investigate 
tissue specificity of our novel candidate markers, we used 
publicly available 450K methylation array data from the 
Marmal-aid database [8], focusing on urological cancers 
and corresponding NM tissue (bladder cancer, N = 85; NM 
bladder, N = 10; kidney cancer, N = 244; NM kidney, N = 
136). We found that hypermethylation of COL4A6, CYBA, 
LINC01341, and RHCG was highly prostate cancer-
specific (Figure S4), suggesting particularly promising 
diagnostic potential for these genes. 
Next, we investigated whether hypermethylation of 
our candidate biomarkers was associated with altered gene 
expression, using a small in-house (14 T, 12 NM) and the 
large TCGA (297 T, 34 NM) RNA-seq datasets. While the 
non-coding LINC01341 lacked annotation in both datasets, 
6 of the remaining 7 candidate genes were downregulated 
in T vs. NM samples, consistent with epigenetic silencing 
through aberrant promoter hypermethylation (Figure S5, 
Table S3). TCAF1 was not significantly deregulated in 
the large TCGA dataset, yet we observed a modest but 
significant upregulation of this transcript in prostate cancer 
in the small dataset. Notably, aberrant hypermethylation 
of TCAF1 was specific to an intragenic CGI/shore region 
overlapping a putative alternative transcription start site 
(TSS), suggesting that hypermethylation of this region 
may stimulate transcription from the upstream TSS (TSS1, 
Figure S1H) in at least some prostate cancers. 
Together, these data indicate that COL4A6, CYBA, 
HLF, LINC01341, LRRC4, PROM1, RHCG, and TCAF1 
are frequent targets of hypermethylation in prostate cancer, 
and that aberrant promoter hypermethylation contributes 
to downregulation of 6 of these genes in this malignancy.
Table 1: Clinicopathological characteristics of patients in RP cohorts 1 and 2
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Figure 3: Diagnostic potential of candidate methylation markers in T, AN and BPH samples (cohort 1). ROC analysis of 
NM samples (AN and BPH, N = 30) vs. T samples (N = 203). Left: Box plots of methylation levels in NM and T samples. (**) P < 0.001, 
rank-sum test. Right: ROC curves of data displayed in box plots. A. COL4A6. B. CYBA. C. HLF. D. LINC01341. E. LRRC4. F. PROM1. 
G. RHCG. H. TCAF1. 
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Diagnostic potential
To investigate the diagnostic potential of our 8 
candidates, methylation levels were examined in 203 T 
and 30 NM prostate tissue samples (cohort 1, Table 1) 
using methylation-specific qPCR (qMSP). For all 8 loci, 
T samples displayed highly significant hypermethylation 
compared to NM samples (Figure 3) with AUCs ranging 
from 0.79 (HLF) to 0.91 (LINC01341). At 96.7% fixed 
specificity (Table S4), sensitivities ranged from 52.2% 
(HLF) to 82.8% (TCAF1). To further examine the 
diagnostic potential, we performed qMSP analysis on 25 
malignant and 50 NM (25 AN + 25 N) diagnostic needle 
biopsy (DNB) specimens. Again, highly significant 
cancer-specific hypermethylation was observed for 
all 8 candidates, with AUCs ranging from 0.97 (HLF) 
to 1.00 (PROM1, TCAF1) (Figure S6). At 96% fixed 
specificity (Table S4), sensitivities ranged from 88% (HLF, 
LINC01341) to 96% (COL4A6, TCAF1, LRRC4).
These results from qMSP analysis of both surgical 
and DNB specimens confirmed that all 8 genes are highly 
frequent targets of prostate cancer-specific aberrant 
hypermethylation, and that our qMSP assays can be used 
on DNBs.
Prognostic potential of single candidates
To investigate their possible prognostic potential in 
prostate cancer, methylation levels of each candidate was 
initially compared to routine clinicopathological factors 
in radical prostatectomy (RP) cohort 1, as well as in an 
independent validation cohort including 286 RP patients 
(cohort 2, Table 1). For all 8 candidates, a significant 
correlation between high methylation and at least one 
established adverse prognostic factor (high GS, advanced 
pathological tumor stage (pT), high pre-operative PSA) 
was observed in at least one cohort (Figure S7, Table 
S5). There were no significant correlations between 
methylation levels and age (Table S5).
To further assess the prognostic value of the 8 
candidates, we investigated whether methylation levels 
were associated with time to biochemical recurrence 
(BCR) after RP. Initially, candidate gene methylation 
(as a continuous variable) was investigated in univariate 
Cox regression analysis in RP cohort 1. Here, COL4A6, 
PROM1, RHCG, and TCAF1 were significant predictors 
of BCR (adj. P ≤ 0.006, Table S6). These results were 
subsequently tested and successfully validated by 
univariate Cox regression analysis in RP cohort 2 (adj. P ≤ 
0.008, Table S6). All routine clinicopathological variables 
were also significant predictors of BCR in univariate Cox 
regression analyses in both cohorts (Table S6), indicating 
that these are representative RP cohorts. 
Next, in cohort 1, we performed multivariate Cox 
regression analysis including the 4 candidates significant 
in univariate analysis, in addition to GS, pT stage, surgical 
margin (SM) status, and pre-operative PSA. Here, both 
RHCG and TCAF1 were significant predictors of BCR, 
independent of routine clinicopathological parameters 
(RHCG hazard ratio (HR) (95% confidence interval 
(CI)): 1.60 (1.07-2.38), P = 0.021; TCAF1 HR (95% CI): 
2.82 (1.54-5.17), P = 0.001, Table 2). The independent 
prognostic potentials of RHCG and TCAF1 were 
subsequently tested in the validation cohort, where both 
candidates were significant adverse predictors of BCR, 
independent of clinicopathological variables (RHCG HR 
(95% CI): 1.55 (1.23 - 1.94), adj. P = 0.001; TCAF1 HR 
(95% CI): 1.48 (1.18 - 1.85), adj. P = 0.001, Table 2). 
Thus, RHCG and TCAF1 hypermethylation, in addition to 
routine clinicopathological parameters, were independent 
predictors of BCR in multivariate analysis in both RP 
cohorts. 
We applied Harrell’s C-index to estimate the 
predictive accuracy of the multivariate model. In cohort 
1, adding RHCG and TCAF1 methylation to a model of 
clinicopathological factors (GS, pT, SM, pre-op. PSA) 
improved the C-index from 0.769 to 0.782, whereas in 
cohort 2, adding RHCG and TCAF1 methylation to the 
clinicopathological model (GS, pT, pre-op. PSA) increased 
the C-index from 0.703 to 0.718, indicating that RHCG 
and TCAF1 methylation improved the predictive accuracy 
in both cohorts and thus carries prognostic potential 
beyond that of routinely used clinicopathological factors.
In order to simplify test interpretation in the clinic, 
biomarkers are often analyzed as dichotomized variables. 
Thus, using cohort 1 for training, RHCG and TCAF1, 
respectively, were divided into high- or low- methylation 
by receiver operating characteristics (ROC) analysis 
(BCR status at 36 months follow-up) and analyzed for 
their ability to predict BCR. In cohort 1, high methylation 
of each candidate significantly predicted BCR in both 
Kaplan-Meier (adj. P = 0.0001, Figure 4), uni- and 
multivariate Cox regression analyses (adj. P < 0.05, Tables 
S7-S9).
Using the numerical cut-offs defined in cohort 
1, we subsequently tested and validated the prognostic 
potential of dichotomized RHCG and TCAF1 in Kaplan-
Meier (adj. P < 0.013, Figure 4), uni- and multivariate Cox 
regression analyses (adj. P ≤ 0.04, Tables S7-S9) in cohort 
2. Thus, dichotomized RHCG and TCAF1 methylation, 
in addition to routine clinicopathological parameters, 
were independent predictors of BCR in both cohorts. 
Moreover, adding these methylation candidate markers 
to the clinicopathological models increased the C-indices 
in both cohorts (Table S8 and S9). Together, these results 
indicate that dichotomized RHCG and TCAF1 improved 
the predictive accuracy beyond routine clinicopathological 
prognostic variables in both cohorts. 
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Prognostic methylation panel
Prostate cancer is a highly heterogeneous disease 
at the molecular level, and multi-gene panels may 
improve the robustness of individual markers [9]. Thus, 
we generated a 2-gene panel consisting of dichotomized 
RHCG and TCAF1 (termed dRHCG-TCAF1), where 
patients with high methylation of both genes were 
classified into the high-methylation group, and the 
remaining patients into the low-methylation group. In 
cohort 1, high methylation of dRHCG-TCAF1 significantly 
predicted BCR in univariate (p < 0.001, Table 3) and 
multivariate Cox regression analyses (HR (95% CI): 2.09 
(1.26-3.46), P = 0.004, Table 3), as well as in Kaplan-
Meier analysis (p < 0.0001, Figure 5A). The prognostic 
potential of dRHCG-TCAF1 was subsequently validated 
in cohort 2, where it was a significant adverse predictor 
in both univariate (P = 0.004, Table 3) and multivariate 
(HR (95% CI): 1.81 (1.05-3.12), P = 0.032, Table 3) Cox 
regression analyses, as well as in Kaplan-Meier analysis (P 
= 0.0008, Figure 5B). In cohort 1, the C-index increased 
from 0.769 to 0.777 when dRHCG-TCAF1 methylation 
was added to the clinicopathological model, whereas in 
cohort 2, it increased from 0.703 to 0.717 by addition of 
dRHCG-TCAF1 methylation, indicating improved model 
performance by adding the 2-gene panel to the established 
prognostic parameters. Thus, dRHCG-TCAF1 methylation, 
together with all available clinicopathological parameters, 
independently predicted BCR in multivariate analysis in 
both RP cohorts. 
Next, we investigated the prognostic potential of a 
trichotomized methylation model (tRHCG-TCAF1), where 
patients in cohort 1 were stratified into 3 groups based on 
whether they had high methylation of both candidates 
(high-methylation), one candidate (intermediate-
methylation), or neither candidate (low-methylation). By 
Kaplan-Meier analysis, patients in the high-methylation 
group had significantly higher risk of BCR than patients 
in the 2 remaining groups, where patients with low 
methylation also had the lowest risk of BCR (P = 0.0001, 
Figure 6A). This was successfully validated in cohort 2 
Figure 4: Kaplan-Meier analysis of association between methylation levels of candidate biomarkers and time to BCR 
after RP. Patients were divided into high- or low methylation groups based on ROC analysis of BCR status (36 months after RP, cohort 
1). A, B: RHCG analyzed in cohort 1 (A) and cohort 2 (B). C, D: TCAF1 analyzed in cohort 1 (C) and cohort 2 (D). P-values from log-rank 
test, adjusted according to the Hochberg procedure.
Oncotarget8www.impactjournals.com/oncotarget
(P = 0.0050, Figure 6B). Moreover, when comparing the 
high and low-methylation groups only, high methylation 
was a significant predictor of BCR in uni- and multivariate 
Cox regression analyses in cohort 1 (Table S10), and these 
results were successfully validated in cohort 2 (Table S10), 
suggesting that prostate cancer patients can be stratified 
into clinically relevant subgroups based on RHCG and 
TCAF1 methylation. Notably, 3 years after surgery, 61% 
of patients with high methylation of the RHCG-TCAF1 
panel had suffered BCR, compared to 23% of patients 
with low methylation in cohort 1. Likewise, in cohort 2, 
35% of patients with high RHCG-TCAF1 methylation had 
suffered BCR 3 years after surgery, compared to 23% of 
patients with low methylation. In summary, these results 
suggest that high methylation of the 2-gene panel RHCG-
TCAF1 is a significant adverse predictor of BCR after RP, 
independent of routine clinicopathological parameters. 
DISCUSSION
Here, we identified COL4A6, CYBA, HLF, 
LINC01341, LRRC4, PROM1, RHCG, and TCAF1 as 
novel targets of frequent hypermethylation in prostate 
cancer. Cancer-specific hypermethylation was observed 
for all candidates in both surgical and DNB specimens, 
suggesting promising diagnostic biomarker potential. 
Furthermore, we generated a new 2-gene panel comprising 
RHCG and TCAF1 methylation, which predicted BCR in 
two RP cohorts from Denmark, Switzerland, and the U.S. 
independently of routine clinicopathological parameters. 
This is the first study to demonstrate a significant 
prognostic value of RHCG and TCAF1 hypermethylation 
in prostate cancer. 
In addition to technical validation by BS, 
hypermethylation in prostate cancer of our eight candidates 
was confirmed in the large external TCGA dataset (450K), 
Figure 6: Kaplan-Meier analysis of the association between methylation levels of the marker panel tRHCG-TCAF1 
and time to BCR after RP. Patients in cohort 1 (A) and cohort 2 (B) divided into high-, low- and intermediate methylation groups. 
High: High methylation of both candidates. Low: Low methylation of both candidates. Intermediate: High methylation of one candidate 
only. RT: RHCG-TCAF1 panel. P-values from log-rank test.
Figure 5: Kaplan-Meier analysis of the association between methylation levels of the marker panel dRHCG-TCAF1 
and time to BCR after RP. Patients in cohort 1 (A) and cohort 2 (B) divided into high-and low methylation groups: High: High 
methylation of both candidates. Low: High methylation of only one, or low methylation of both candidates. RT: RHCG-TCAF1 panel. 
P-values from log-rank test.
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further supporting their diagnostic potential. Moreover, 
as proof of principle, we demonstrated that our qMSP 
assays can be used on DNBs despite scarce sample 
amounts. While a molecular diagnostic test that can detect 
histologically verified prostate cancer in DNBs might 
have limited clinical utility, detection of methylation-
based cancer field effects in morphologically normal 
prostate biopsies may be used to guide the need for repeat 
biopsy in men with exclusively cancer-negative DNBs but 
persistently elevated PSA, which remains a major clinical 
challenge [10, 11]. Although we did not detect significant 
differential methylation between AN and N samples in this 
study, our analysis could be limited by the relatively small 
sample size. Further studies are needed to investigate the 
possible existence of epigenetic cancer field effects for our 
candidate genes. Future studies should also investigate 
whether our novel candidate markers are detectable in 
blood or urine samples, e.g. as circulating cell-free tumor 
DNA methylation, which could facilitate development of 
minimally or non-invasive testing for prostate cancer.
Here, using two large prostate cancer patient 
cohorts, we identified and independently validated 
RHCG, TCAF1, and the 2-gene panel RHCG-TCAF1 as 
novel independent adverse predictors of BCR after RP. 
Prior to this, only a few candidate methylation markers 
have demonstrated prognostic potential in more than one 
prostate cancer cohort by multivariate analysis adjusting 
for established clinicopathological parameters [3]. These 
are PITX2 [12, 13], GABRE~miR-452~miR-224 [14], 
C1orf114 (CCDC181) [9], and the panels C1orf114/
HAPLN3 and AOX1/C1orf114/HAPLN3 [9]. Further 
studies, using large independent cohorts with long follow-
Table 2: Multivariate analysis. 
Multivariate Cox regression analysis of methylation marker candidates and clinicopathological variables analyzed as 
continuous variables with stepwise backwards selection in cohort 1 (top) and of RHCG and TCAF1 in cohort 2 (middle and 
bottom). Only candidate genes significant in cohort 1 (training) were tested in cohort 2 (validation). Bold: P<0.05. NA, not 
applicable.
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up, are needed to assess the clinical utility of RHCG and 
TCAF1 as well as of the previously identified prognostic 
methylation marker candidates. These candidates should 
be investigated individually, as well as in combinations, 
to identify their true prognostic potential.
Current prognostic prostate cancer classification 
systems rely on histopathological criteria, which cannot 
accurately predict whether a tumor will progress to 
clinically relevant disease or remain indolent. Novel 
biomarkers that enable distinction between aggressive 
and indolent cancer at the time of diagnosis could improve 
patient management significantly, e.g. by allowing 
active surveillance of low-risk patients and immediate 
treatment of high-risk patients. While the incremental 
gain in prognostic information obtained by adding 
parameters to existing models is often modest [15], the 
increased C-indices presented here nevertheless represent 
meaningful improvements to the model comprising only 
clinicopathological parameters [16]. The full multivariate 
model including the dichotomized methylation marker 
panel dRHCG-TCAF1 provided a C-index of 0.777 
in cohort 1 and 0.717 in cohort 2. C-index analysis in 
reduced models, i.e. leaving out one variable at a time, 
demonstrated modest C-index contributions for any single 
variable (range 0.008-0.028 in cohort 1 and 0.011-0.032 
in cohort 2), corresponding to a maximum contribution of 
3.6% and 5.2% in cohort 1 and 2, respectively (data not 
shown). Moreover, the observed increments in C-index for 
our novel 2-gene methylation marker panel are comparable 
to those reported for other prognostic DNA methylation 
marker candidates [9, 13, 14], as well as for prognostic 
gene expression signatures that have been developed into 
commercial tests for prostate cancer, i.e. Decipher [17], 
Oncotype [18] and Prolaris [19]. 
Furthermore, as cancer-specific hypermethylation 
was detectable in DNBs, our results suggest that RHCG-
TCAF1 has the potential to improve the accuracy of 
prostate cancer prognosis at the time of diagnosis, where 
only pre-operative clinicopathological parameters are 
available (biopsy-based GS, clinical tumor stage, and 
pre-operative PSA). Notably, more than 50% of prostate 
tumors are upstaged and/or upgraded after RP [20], further 
stressing the need for improved prognostic markers at an 
early stage. Thus, it is likely that our methylation marker 
candidates would contribute relatively more independent 
prognostic information in biopsy specimens at the time 
of diagnosis, than shown here for RP samples, and thus 
potentially could be used to guide treatment decisions in 
the future. Moreover, our qMSP assays are simple and 
cost-effective and as such would be easy to incorporate 
into routine diagnostic practice. 
The potential functional roles of our 8 candidate 
methylation markers in prostate physiology and 
malignancy are largely unknown. Here, we found 
that expression of 6 of these genes was significantly 
downregulated in prostate cancer, consistent with 
epigenetic silencing and suggesting a possible function in 
prostate carcinogenesis and/or tumor progression. More 
specifically, we observed promoter hypermethylation and 
downregulation of RHCG in prostate tumors, which is 
consistent with previous reports of RHCG downregulation 
in kidney and oesophagal carcinomas [21, 22]. RHCG 
encodes an epithelial ammonia transporter that is widely 
expressed in the kidney, liver and intestinal tract, as well 
as in male reproductive organs, where it contributes to 
multiple components of fertility [23]. The role of RHCG in 
the normal and cancerous prostate, however, is unknown 
and further studies are warranted.
TCAF1 was recently identified as a positive 
regulator of TRPM8, an ionotropic testosterone receptor 
highly expressed in various organs, including the prostate 
[24, 25], but its exact function in the prostate is unknown 
[25, 26]. According to our analysis, TCAF1 expression 
was unaltered or modestly upregulated in localized 
prostate tumors compared to NM prostate tissue samples, 
consistent with a previous study [24]. Several studies have 
Table 3: Uni- and multivariate Cox regression analysis of the dichotomized RHCG-TCAF1 panel
Analyses performed in cohort 1 (top) and 2 (bottom). Bold: P<0.05. aModel including all variables significant in multivariate 
analysis. bModel including clinicopathological variables only. 
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reported that intragenic DNA methylation, as we observed 
for TCAF1 in prostate cancer, is involved in alternative 
TSS-regulation in normal and malignant tissue [27]. 
Moreover, gene body methylation is a feature of actively 
transcribed genes [28]. Future studies should investigate 
TCAF1 methylation and potential isoform-specific 
expression patterns in NM and malignant prostate cells to 
elucidate its possible role in prostate cancer tumorigenesis 
and progression.
We observed cancer-specific promoter 
hypermethylation and downregulation of PROM1 
(CD133) expression, which is consistent with reports 
of PROM1 downregulation in several malignancies, 
including prostate cancer [29, 30]. PROM1 encodes 
a transmembrane glycoprotein widely used as a stem 
cell marker, but its potential role in prostate cancer is 
unknown. We also observed cancer-specific promoter 
hypermethylation and downregulation of COL4A6, which 
encodes a subunit of the epithelial basement membrane 
protein collagen IV. Our observations are consistent 
with reports of COL4A6 downregulation in a range of 
cancers, including prostate cancer [31]. Cancer-specific 
hypermethylation and transcriptional downregulation was 
also observed for CYBA, HLF, and LRRC4. CYBA encodes 
a subunit of an NADPH oxidase, whereas HLF encodes 
a transcriptional activator of the proline and acidic-rich 
(PAR) protein family. LRRC4 is a proposed TSG involved 
in nervous system development and differentiation 
[32], and was reported to be hypermethylated and 
downregulated in gliomas [33]. However, the roles of 
these genes in prostate physiology and malignancy are 
unknown. Finally, we observed cancer-specific promoter 
hypermethylation of the verified but uncharacterized 
long non-coding RNA LINC01341 [34]. Unfortunately, 
no expression data was available for LINC01341 in the 
investigated datasets. Thus, further studies are needed to 
elucidate the possible role of LINC01341 in normal and 
malignant prostate biology.
There are some limitations to the present study. The 
prognostic analyses for our candidates were based on RP 
specimens, and while it could be useful to identify high-
risk patients in need of adjuvant therapy post-RP (e.g. 
radiation treatment or androgen deprivation), there are 
currently no established adjuvant lines of treatment for 
patients after RP. Thus, future studies should evaluate the 
prognostic potential of these novel candidate methylation 
markers in DNBs, and thus investigate whether they 
can predict prostate cancer aggressiveness at the time of 
diagnosis and thereby help guide treatment decisions. 
Moreover, the RP cohorts used for analysis of 
prognostic biomarker potential were of moderately 
different compositions, with patients in cohort 1 suffering 
more BCRs and having tumors with higher pT stage 
and higher median pre-operative PSA compared to 
patients in cohort 2 (Table 1). Nevertheless, all routine 
clinicopathological variables (GS, pT, pre-op. PSA) were 
significant predictors of BCR in uni- and multivariate Cox 
regression analysis in both cohorts, strongly indicating 
that both constitute representative RP cohorts. Moreover, 
our RHCG-TCAF1 panel was significant in multivariate 
analysis in both cohorts, using the exact numerical 
dichotomization/trichotomization cut-points derived from 
cohort 1 (training cohort), thus indicating the robustness 
of our methylation marker candidates. 
Another limitation to our study is the lack of SM 
status information for most patients in cohort 2, thus this 
parameter was excluded from multivariate analysis in this 
cohort. Nevertheless, SM status was a significant predictor 
of BCR in uni- and multivariate Cox regression analysis 
in cohort 1, as were our methylation marker candidates, 
further supporting their strength as independent prognostic 
biomarkers for prostate cancer. Furthermore, the use of 
BCR as end-point for survival analysis constitutes another 
possible limitation. BCR may result from either non-
radical surgery, or micro metastatic disease manifesting 
prior to surgery, and is only a surrogate marker for tumor 
aggressiveness. Thus, future studies should investigate 
our novel methylation marker candidates in relation to 
more clinically relevant endpoints, such as metastatic 
progression or prostate cancer-specific mortality. Due 
to the slow progression of prostate cancer, such studies 
would require large cohorts with > 15 years of follow-up 
[35]. Finally, while the cohorts used in this study included 
patients of European descent, further studies are needed to 
investigate if our findings can be extended to other ethnic 
groups. 
In conclusion, we identified and validated 8 
novel methylation marker candidates for prostate 
cancer diagnosis. We also identified and validated 
the prognostic potential of a new 2-gene methylation 
marker panel TCAF1-RHCG, which predicted time to 
BCR independently of established clinicopathological 
parameters in 2 RP cohorts. The actual clinical utility of 
these novel candidate methylation markers for prostate 
cancer diagnosis and prognosis should be further 
investigated in large independent cohorts with long 
follow-up and clinically relevant end-points. Moreover, 
an important future task will be to investigate whether 
methylation of RHCG and TCAF1 can also predict prostate 
cancer aggressiveness at the time of diagnosis based on 
analysis of DNBs or even liquid biopsies, in order to guide 
treatment decisions.
MATERIALS AND METHODS
Infinium HumanMethylation450 BeadChip
A total of 21 T, 14 AN, 9 N prostate tissue samples 
(Table S1), and 5 cell lines (BPH1, 22rv1, LNCaP, PC3, 
and PrEC; Table S11) were analyzed by the Infinium 
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HumanMethylation450 BeadChip (Illumina, San Diego, 
CA). Bisulfite conversion and genome-wide methylation 
analysis was conducted as a commercial service by The 
Genome Centre, Barts and the London School of Medicine 
and Dentistry, London, UK, according to manufacturer’s 
protocol. For further details, see supplementary methods.
Quantitative methylation specific PCR (qMSP)
Patient material
Biopsy sample set: DNB specimens (formalin-fixed, 
paraffin-embedded (FFPE)) from patients undergoing 
transrectal ultrasound-guided biopsy due to suspicion of 
prostate cancer were obtained from Dept. of Pathology, 
Aarhus University Hospital, DK, as described elsewhere 
(Moller et al., Scientific Reports, in press). We obtained 
normal (N) biopsy samples from 25 patients with 
exclusively cancer-negative biopsies, tumor biopsies 
from 25 patients diagnosed with prostate cancer (T), and 
histologically normal (AN) biopsies from 25 patients with 
prostate cancer detected in other biopsies.
Radical prostatectomy cohorts: Cohort 1 (training 
cohort) consisted of 566 curatively intended RP patients 
with histologically verified clinically localized prostate 
cancer (FFPE) from the Dept. of Urology, Aarhus 
University Hospital, DK (collected 1997-2009). All 
specimens were assessed by a trained pathologist. Punch 
biopsies were obtained from FFPE block-areas with > 
80% cancer cells, as described previously [9, 14, 36]. Of 
the 566 patients, 1 withdrew consent, 37 were either lost 
to follow-up, had < 3 months follow-up, or suffered BCR 
within 3 months post-RP, 42 were excluded because of 
pre-/postoperative endocrine treatment or missing data 
for endocrine treatment, 6 were excluded due to positive 
lymph node status, 1 lacked clinical data, and 240 were 
excluded due to lack of tissue in the FFPE block or 
insufficient DNA concentration/quality. Final analyses 
comprised 203 prostate cancer samples (Table 1). 
Cohort 2 consisted of 448 and 117 curatively 
intended RP patients with histologically verified, 
clinically localized prostate cancer (FFPE) from Moffitt 
Cancer Center, U.S. (collected 1987-2006) and University 
Hospital Zurich, Switzerland (collected 1993-2001). Of 
the 565 patients, 19 were either lost to follow-up, had < 
3 months follow-up, or suffered BCR within 3 months 
post-RP, 82 were excluded because of pre-/postoperative 
endocrine treatment or missing data for endocrine 
treatment, 6 were excluded due to positive lymph node 
status, 13 were excluded due to ethnicity (non-European 
descent), 118 lacked clinical data, and 41 lacked tissue in 
the FFPE block or had insufficient DNA concentration/
quality. Final analyses comprised 286 samples (Table 
1). See Figure S8A for flow chart of inclusion/exclusion 
criteria for both cohorts according to REMARK guidelines 
[37]. The compositions of the final cohorts were similar to 
that of the original cohorts (Table S12). 
FFPE AN tissue samples from RP specimens and 
benign prostate hyperplasia (BPH) specimens (trans-
urethral resection of the prostate) were sampled as 
described above for cohort 1 (Table 1, Figure S8B).
DNA purification and bisulfite conversion
For DNA purification from DNBs, 3-µm tissue 
sections were deparaffinized and DNA was extracted using 
the QIAamp DNA FFPE Tissue Kit (Qiagen) according to 
manufacturer’s protocol. DNA from RP specimens (punch 
biopsies) was extracted in Denmark and Switzerland using 
gDNA Eliminator columns from the RNeasy plus micro kit 
(Qiagen) and the blood and cell culture DNA kit (Qiagen), 
respectively, as previously described [9]. DNA from FFPE 
samples from the U.S. was extracted using the QIAamp 
DNA FFPE tissue kit (Qiagen). All DNA samples were 
bisulfite-converted using the EZ-96 DNA Methylation-
Gold KitTM (Zymo research). 
qMSP assays (Table S13) were designed using 
Primer3Plus [38] and Beacon DesignerTM (Premier 
Biosoft) and run as previously described [9]. Briefly, 5 
ng bisulfite-converted DNA was analyzed per reaction. 
DNA and mastermix (Taqman universal mastermix no 
UNG and primer/probe sets) were run in 384-well plates 
on the Applied Biosystems 7900HT real-time thermal 
cycler. Bisulfite-converted and un-converted CpGenome 
Universal Methylated DNA (Millipore), 2 negative 
controls (whole-genome amplified DNA and H
2
O), as well 
as serially diluted methylated DNA samples for standard 
curve analysis, were included on each plate. All reactions 
were run in triplicates. MYOD1 and aluC4 served as 
controls for DNA quality/quantity [9, 39], and aluC4 was 
used for normalization. Samples were excluded from 
further analysis if ≥ 2 aluC4 reactions had Ct > 25 and/
or MYOD1 was not amplified. Samples were considered 
negative for methylation if ≥ 2 methylation-specific 
reactions did not amplify. Bisulfite-converted DNA from 
DNBs was pre-amplified prior to qMSP (Table S13). 
Statistics
Statistical analyses were performed using STATA v. 
11.2 (StataCorp, College Station, TX, USA). Associations 
between DNA methylation and clinicopathological 
variables were assessed by Wilcoxon rank-sum test 
and Spearman correlations. BCR (defined as PSA ≥ 0.2 
ng/ml) was the clinical endpoint in survival analyses. 
Patients without BCR were censored at their last normal 
PSA measurement. In all cases, p < 0.05 was considered 
significant. Where appropriate, correction for multiple 
testing was conducted according to Hochberg [40]. The 
prognostic potential of methylation marker candidates was 
analyzed by uni- and multivariate Cox regression analysis, 
Kaplan-Meier analysis and two-sided log-rank tests. 
Predictive accuracy was estimated using Harrell’s C-index 
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[41]. For multivariate testing, all clinicopathological 
parameters significant in univariate analysis were 
included. SM status was unavailable for U.S. patients, 
and was therefore excluded from multivariate analysis in 
cohort 2.
Prognostic 2-gene model: For each gene, patients 
in cohort 1 (training cohort) were dichotomized into 
high/low-methylation groups by ROC analysis of BCR 
status at 36 months follow-up. Cohort 2 patients were 
dichotomized by the exact numerical cutoff values defined 
in cohort 1 (RHCG: ≥ 0.3608787; TCAF1: ≥ 0.519267). 
For the dichotomized 2-gene panel (dRHCG-TCAF1), 
patients were included in the high-methylation group if 
both genes were highly methylated. For the trichotomized 
2-gene panel (tRHCG-TCAF1), patients were included 
in the high-methylation group if both genes were highly 
methylated, the intermediate group if one gene was highly 
methylated, and the low-methylation group if neither gene 
was highly methylated.
Bisulfite sequencing, RNA-seq, external datasets
See Supplementary Materials and Methods.
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